1. Home
  2. ACRV vs PTMN Comparison

ACRV vs PTMN Comparison

Compare ACRV & PTMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • PTMN
  • Stock Information
  • Founded
  • ACRV 2018
  • PTMN 2006
  • Country
  • ACRV United States
  • PTMN United States
  • Employees
  • ACRV N/A
  • PTMN N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • PTMN Finance: Consumer Services
  • Sector
  • ACRV Health Care
  • PTMN Finance
  • Exchange
  • ACRV Nasdaq
  • PTMN Nasdaq
  • Market Cap
  • ACRV 59.9M
  • PTMN 113.0M
  • IPO Year
  • ACRV 2022
  • PTMN N/A
  • Fundamental
  • Price
  • ACRV $1.18
  • PTMN $12.35
  • Analyst Decision
  • ACRV Strong Buy
  • PTMN Hold
  • Analyst Count
  • ACRV 5
  • PTMN 1
  • Target Price
  • ACRV $19.75
  • PTMN $14.00
  • AVG Volume (30 Days)
  • ACRV 1.3M
  • PTMN 50.9K
  • Earning Date
  • ACRV 05-13-2025
  • PTMN 05-08-2025
  • Dividend Yield
  • ACRV N/A
  • PTMN 17.70%
  • EPS Growth
  • ACRV N/A
  • PTMN N/A
  • EPS
  • ACRV N/A
  • PTMN N/A
  • Revenue
  • ACRV N/A
  • PTMN $62,432,000.00
  • Revenue This Year
  • ACRV N/A
  • PTMN N/A
  • Revenue Next Year
  • ACRV N/A
  • PTMN $4.14
  • P/E Ratio
  • ACRV N/A
  • PTMN N/A
  • Revenue Growth
  • ACRV N/A
  • PTMN N/A
  • 52 Week Low
  • ACRV $1.30
  • PTMN $11.60
  • 52 Week High
  • ACRV $10.29
  • PTMN $20.84
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 29.23
  • PTMN 39.40
  • Support Level
  • ACRV $1.32
  • PTMN $12.11
  • Resistance Level
  • ACRV $1.50
  • PTMN $12.39
  • Average True Range (ATR)
  • ACRV 0.19
  • PTMN 0.27
  • MACD
  • ACRV 0.06
  • PTMN 0.16
  • Stochastic Oscillator
  • ACRV 2.08
  • PTMN 64.06

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

Share on Social Networks: